“LONG COVID”—A hypothesis for understanding the biological basis and pharmacological treatment strategy
Abstract Infection of humans with SARS‐CoV‐2 virus causes a disease known colloquially as “COVID‐19” with symptoms ranging from asymptomatic to severe pneumonia. Initial pathology is due to the virus binding to the ACE‐2 protein on endothelial cells lining blood vessels and entering these cells in o...
Main Authors: | Bevyn Jarrott, Richard Head, Kirsty G. Pringle, Eugenie R. Lumbers, Jennifer H. Martin |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-02-01
|
Series: | Pharmacology Research & Perspectives |
Subjects: | |
Online Access: | https://doi.org/10.1002/prp2.911 |
Similar Items
-
SARS-CoV-2, platelets, and endothelium: coexistence in space and time, or a pernicious ménage à trois?
by: Vladimir Y Bogdanov, et al.
Published: (2022-07-01) -
Long COVID 19 Syndrome: Is It Related to Microcirculation and Endothelial Dysfunction? Insights From TUN-EndCOV Study
by: Salma Charfeddine, et al.
Published: (2021-11-01) -
Red Blood Cell Adenylate Energetics Is Related to Endothelial and Microvascular Function in Long COVID
by: Marzena Romanowska-Kocejko, et al.
Published: (2024-03-01) -
The Lung, the Heart, the Novel Coronavirus, and the Renin-Angiotensin System; The Need for Clinical Trials
by: Eugenie R. Lumbers, et al.
Published: (2020-05-01) -
Possible Application of Melatonin in Long COVID
by: Daniel P. Cardinali, et al.
Published: (2022-11-01)